ResearcherJohns Hopkins UniversityActive in the last 2 years
Parul Agarwal
Matched on ORCID iD 0000-0001-9549-5023; OpenAlex author ID A5090120270. Sources: OpenAlex.
Their work
- Papers
- 3 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 23
2019: 1 paper · 2020: none · 2021: none · 2022: 1 paper · 2023: none · 2024: none · 2025: 1 paper
Papers 3
- A Phase II Study of Neoadjuvant GVAX and Cyclophosphamide Combined with Nivolumab and SBRT Followed by Surgery in Borderline Resectable Pancreatic Adenocarcino… Co-author DOI 10.1158/1078-0432.ccr-24-3403↗
- Cell-free DNA Predicts Prolonged Response to Multi-agent Chemotherapy in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/2767-9764.crc-22-0343↗
- Retrospective Survival Analysis of Patients With Resected Pancreatic Ductal Adenocarcinoma and a Germline BRCA or PALB2 Mutation. First author DOI 10.1200/po.18.00271↗
Closest collaborators
The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Hao Wang · 2 shared papers, 2022–2025 · strength 0.34
- Paper A Phase II Study of Neoadjuvant GVAX and Cyclophosphamide Combined with Nivolumab and SBRT Followed by Surgery in Borde… DOI 10.1158/1078-0432.ccr-24-3403↗
- Paper Cell-free DNA Predicts Prolonged Response to Multi-agent Chemotherapy in Pancreatic Ductal Adenocarcinoma. DOI 10.1158/2767-9764.crc-22-0343↗
- Ana De Jesus‐Acosta · 2 shared papers, 2022–2025 · strength 0.34
- Paper A Phase II Study of Neoadjuvant GVAX and Cyclophosphamide Combined with Nivolumab and SBRT Followed by Surgery in Borde… DOI 10.1158/1078-0432.ccr-24-3403↗
- Paper Cell-free DNA Predicts Prolonged Response to Multi-agent Chemotherapy in Pancreatic Ductal Adenocarcinoma. DOI 10.1158/2767-9764.crc-22-0343↗
- Daniel A. Laheru · 2 shared papers, 2022–2025 · strength 0.34
- Paper A Phase II Study of Neoadjuvant GVAX and Cyclophosphamide Combined with Nivolumab and SBRT Followed by Surgery in Borde… DOI 10.1158/1078-0432.ccr-24-3403↗
- Paper Cell-free DNA Predicts Prolonged Response to Multi-agent Chemotherapy in Pancreatic Ductal Adenocarcinoma. DOI 10.1158/2767-9764.crc-22-0343↗
- Robert A. Anders · 1 shared paper, 2025 · strength 0.19
- Jin Peng He · 1 shared paper, 2025 · strength 0.19
- Ben George · 1 shared paper, 2025 · strength 0.19
- Richard Andrew Burkhart · 1 shared paper, 2025 · strength 0.19
- Mark M. Yarchoan · 1 shared paper, 2025 · strength 0.19
- Matthew Z. Guo · 1 shared paper, 2025 · strength 0.19
- Elizabeth M. Jaffee · 1 shared paper, 2025 · strength 0.19
- Lei Zheng · 1 shared paper, 2025 · strength 0.19
- Arsen Osipov · 1 shared paper, 2025 · strength 0.19
- Amol Kumar Narang · 1 shared paper, 2025 · strength 0.19
- Eric Scott Christenson · 1 shared paper, 2022 · strength 0.15
- Dung Thi Le · 1 shared paper, 2022 · strength 0.15
- Katherine M. Bever · 1 shared paper, 2022 · strength 0.15
- Peter James O'Dwyer · 1 shared paper, 2019 · strength 0.09
- Susan M. Domchek · 1 shared paper, 2019 · strength 0.09
- Katherine L. Nathanson · 1 shared paper, 2019 · strength 0.09
- Ronac Mamtani · 1 shared paper, 2019 · strength 0.09
- Shun Yu · 1 shared paper, 2019 · strength 0.09
- Mark H. O’Hara · 1 shared paper, 2019 · strength 0.09
- Kim A. Reiss · 1 shared paper, 2019 · strength 0.09
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.